Search

Your search keyword '"Orit Freedman"' showing total 2 results
Start Over Author "Orit Freedman" Journal breast cancer research
2 results on '"Orit Freedman"'

1. A randomized, phase III trial exploring the effects of neoadjuvant sequential treatment with steroidal (exemestane) and nonsteroidal (anastrozole) aromatase inhibitors on biomarkers in postmenopausal women with hormone receptor-positive locally advanced breast cancer

Author

Mitchell Dowsett, Harriette J. Kahn, Orit Freedman, Dec Cole, Mark Clemons, Sunil Verma, G. Dranitsaris, Frances P O'Malley, and Eitan Amir

Subjects
Oncology, medicine.medical_specialty, Aromatase inhibitor, biology, medicine.drug_class, business.industry, medicine.medical_treatment, Anastrozole, Pharmacology, medicine.disease, chemistry.chemical_compound, Breast cancer, Exemestane, chemistry, Surgical oncology, Internal medicine, Poster Presentation, medicine, biology.protein, Endocrine system, Aromatase, business, Adjuvant, medicine.drug
Abstract

Despite many large randomised trials assessing adjuvant endocrine treatment for postmenopausal breast cancer patients, the optimal endocrine strategy remains unknown. Neoadjuvant endocrine studies provide the opportunity to model an appropriate study design in a more expeditious manner. Several large adjuvant trials are exploring sequential aromatase inhibitor (AI) strategies. The present study compared the effect of two sequences of AI use – steroidal (exemestane (E)) and nonsteroidal (anastrozole (A)) – on serological and pathological biomarkers, when given in the neoadjuvant setting to patients with locally advanced breast cancer.

Published
2009

2. Developing a prediction model for benefit from fulvestrant in heavily pretreated metastatic breast cancer patients

Author

I Ahmad, Mark Clemons, G. Dranitsaris, Katia Tonkin, S Dent, Teresa M. Petrella, Eitan Amir, Stephen Chia, Orit Freedman, and Daniel Rayson

Subjects
Oncology, medicine.medical_specialty, Breast cancer, Fulvestrant, business.industry, Surgical oncology, Internal medicine, Poster Presentation, Medicine, business, medicine.disease, Metastatic breast cancer, medicine.drug
Abstract

Fulvestrant use in heavily pretreated patients with metastatic breast cancer is associated with highly variable responses. The present study aimed to characterize the benefit of fulvestrant therapy and to develop a prediction model for clinical benefit in this setting.

Published
2009

Catalog

Books, media, physical & digital resources
See catalog results